Beckman Coulter Diagnostics

Executive Summary

Beckman Coulter Diagnostics is a leading global provider of clinical diagnostic systems, instruments, and reagents, serving core laboratory disciplines including chemistry, immunoassay, hematology, urinalysis, microbiology, and blood banking. With a history dating back to 1935, the company has built a reputation for delivering accurate and timely diagnostic information that enables better patient care and clinical outcomes. As a private entity (part of the Danaher Corporation portfolio), Beckman Coulter benefits from significant R&D investment and a broad commercial footprint, allowing it to compete effectively against larger players like Abbott, Roche, and Siemens. The company is focusing on digital transformation and automation to enhance laboratory efficiency, with integrated solutions that reduce turnaround times and improve workflow. Recent launches, such as the DxH 900 hematology analyzer and the Access immunoassay systems, underscore its commitment to innovation. Despite competitive pressures, Beckman Coulter's strong installed base and recurring reagent revenue provide stability. The company is also expanding its menu of specialty assays and investing in point-of-care and molecular diagnostics to capture growth in decentralized testing. With Danaher's support, Beckman Coulter is well-positioned to benefit from the increasing global demand for diagnostic testing, driven by aging populations and the rise of chronic diseases.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for New High-Sensitivity Troponin Assay85% success
• Q4 2026Launch of Next-Generation Automation Platform for Core Labs70% success
• Q2 2026Expansion of Test Menu with Novel Infectious Disease Assays80% success